Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 2Gastrointestinal 2Plasma cell 1Other hematologic neoplasm 1Head & Neck 1Endocrine 1CNS 1

Conditions

Multiple Myeloma 14Hematologic Neoplasms 7Lymphoma 5Neoplasms 4Glioma 3Thyroid Carcinoma, Anaplastic 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Lymphoma, Non-Hodgkin 2Colorectal Neoplasms 2Breast Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Thrombocytosis 1Stomach Neoplasms 1Recurrence 1Rectal Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Nonseminomatous germ cell tumor 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1

Interventions

trametinib 1dabrafenib 1Thalidomide 1Imatinib Mesylate 1Fentanyl 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gastrointestinal Stromal Tumors × trametinib × Plasma cell × Clear all
NCT02034110 2023-08-21

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

Novartis

Phase 2 Completed
206 enrolled 40 charts 2 FDA
CNSEndocrineGastrointestinalHead & NeckOther hematologic neoplasmPlasma cellSarcoma

Nonseminomatous germ cell tumor, Biliary Tract Neoplasms, Glioma, Leukemia, Hairy Cell, Multiple Myeloma, Neoplasms, Gastrointestinal Stromal Tumors, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡